News
NBIX
99.93
+1.72%
1.69
IBD Screen Of The Day: These Top Stocks To Watch Outperform The Market
By scanning for stocks with a relative strength line at new highs in the IBD Stock Screener, we can look for these outperformers.
Investor's Business Daily · 6d ago
Neurocrine Biosciences Presents Data on Treatment of Adolescent Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2022
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present new Phase 2 data on the use of crinecerfont in adolescent patients with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21-OHD), which demonstra...
PR Newswire · 06/13 12:00
Research Alert: CFRA Keeps Hold Opinion On Shares Of Neurocrine Biosciences
MT Newswires · 06/10 14:00
Neurocrine Biosciences to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Goldman Sachs 43rd Annual Global Healthcare Conference at 10:40 a.m. Pacific Time (1:40 p.m. Eastern Time) on Wednesday, June 15, 2022 in Rancho Palos Verdes, CA. Kevin Gorman, Chief Executive...
PR Newswire · 06/08 20:01
Neurocrine Biosciences Honored at CARES Foundation 22nd Anniversary Gala
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) was honored by the CARES Foundation for its ongoing research and development of novel therapies for patients with classic congenital adrenal hyperplasia (CAH). The CARES Foundation, Inc. is the only U.S.-based no...
PR Newswire · 06/06 13:30
Neurocrine Biosciences Presents Data on Sleep Disturbances and OFF Time in Patients with Parkinson's Disease and Motor Fluctuations at SLEEP 2022
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presents data on sleep disturbances in Parkinson's disease (PD) demonstrating the impact of OFF episodes, or reemergence of symptoms between doses of levodopa, on falling asleep and staying asleep. These da...
PR Newswire · 06/06 12:30
Jefferies Assumes Neurocrine Biosciences at Buy with $112 Price Target
MT Newswires · 06/06 10:16
Neurocrine Biosciences to repurchase $179.4M of 2.25% Convertible Senior Notes due 2024
Neurocrine Biosciences (NASDAQ:NBIX) plans to repurchase ~$179.4M aggregate principal amount of its existing 2.25% Convertible Senior Notes due 2024. It entered into separate, privately negotiated transactions with certain holders of
Seekingalpha · 05/25 10:05
Neurocrine Biosciences to Repurchase $179.4 Million of Convertible Notes
MT Newswires · 05/25 03:15
BRIEF-Neurocrine Biosciences Says Entered In Transactions With Holders Of Existing 2.25% Convertible Senior Notes Due 2024 To Repurchase $179.4 Mln
reuters.com · 05/25 01:47
BRIEF-Neurocrine Biosciences Presents New Valbenazine Data At American Psychiatric Association Annual Meeting
reuters.com · 05/23 12:55
Neurocrine Biosciences Highlights Presentation Of New INGREZZA Data On Tardive Dyskinesia Improvement, Stability Of Psychiatric Symptoms At American Psychiatric Association Meeting Jun. 7-10
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced that it will present data on the use of INGREZZA® (valbenazine) capsules for the treatment of tardive dyskinesia (TD) at the American Psychiatric
Benzinga · 05/23 12:34
Neurocrine Biosciences Presents New INGREZZA® (valbenazine) Data on Tardive Dyskinesia Improvement and Stability of Psychiatric Symptoms at American Psychiatric Association Annual Meeting 2022
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present data on the use of INGREZZA® (valbenazine) capsules for the treatment of tardive dyskinesia (TD) at the American Psychiatric Association (APA) Annual Meeting being held in per...
PR Newswire · 05/23 12:30
Neurocrine Biosciences Earnings Perspective: Return On Capital Employed
According to Benzinga Pro, during Q1, Neurocrine Biosciences (NASDAQ:NBIX) earned $13.90 million, a 290.41% increase from the preceding quarter. Neurocrine Biosciences's sales decreased to $310.60 million, a 0.45% change since Q4.
Benzinga · 05/19 13:52
Neurocrine Biosciences valbenazine gets FDA orphan drug status for Huntington disease
The U.S. Food and Drug Administration (FDA) granted orphan drug designation to Neurocrine Biosciences' (NASDAQ:NBIX) valbenazine to treat Huntington disease (HD). The company said treatment of chorea associated with HD is
Seekingalpha · 05/13 10:08
Neurocrine Biosciences Gets FDA's Orphan Drug Designation for Experimental Huntington Disease Drug
MT Newswires · 05/13 03:46
BRIEF-Neurocrine Biosciences Receives Orphan Drug Designation For Valbenazine As A Treatment For Chorea Associated With Huntington Disease
reuters.com · 05/12 23:39
Neurocrine Biosciences Receives Orphan Drug Designation for Valbenazine as a Treatment for Chorea Associated with Huntington Disease
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for valbenazine as a treatment for Huntington disease (HD). The treatment of chorea associated with HD...
PR Newswire · 05/12 23:37
Insider Sell: Neurocrine Biosciences
MT Newswires · 05/11 17:52
Pfizer deal to buy Biohaven rallies biotech
The decision by Pfizer (NYSE:PFE) to acquire the commercial-stage biopharma company, Biohaven Pharmaceutical (BHVN) for nearly $12 billion has revived the beaten-down biotech space on Tuesday. SPDR S&P Biotech ETF (XBI)
Seekingalpha · 05/10 14:14
More
Webull provides a variety of real-time NBIX stock news. You can receive the latest news about Neurocrine Biosciences Inc through multiple platforms. This information may help you make smarter investment decisions.
About NBIX
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is focused on discovering, developing and marketing of pharmaceuticals for the treatment of neurological, endocrine and psychiatric-based diseases and disorders. Its portfolio includes treatments for tardive dyskinesia, Parkinson’s disease, endometriosis and uterine fibroids. Its product pipeline includes INGREZZA (valbenazine), which provides a once-daily dosing treatment option for tardive dyskinesia and has three dosing options (40 milligram (mg), 60 mg and 80 mg capsules); ONGENTYS (opicapone) is an adjunctive therapy to levodopa/carbidopa in patients with Parkinson’s disease; ORILISSA (elagolix) is used for the management of moderate to severe endometriosis pain in women, and ORIAHNN (elagolix, estradiol, and norethindrone acetate and elagolix capsules) is a non-surgical, oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in women.